cdc.gov/coronavirus

ACIP COVID-19 Vaccines Work Group

Dr. Matt Daley, Work Group Chair

June 23, 2021
▪ Since December, three COVID-19 vaccines authorized under EUA and 

recommended for use in the US

COVID-19 Pandemic and vaccines

2

December 2020:

250,000 cases/day

3,000 deaths/day

June 2021:

13,000 cases/day

300 deaths/day

As of June 21:

318 million vaccine doses administered

150 million people fully vaccinated 

53% of population ≥12 years of age
▪ Meets weekly 

▪ Topics covered:

– Review of vaccines and SARS-CoV-2 variants

– Data needed to inform discussions around additional doses of COVID-19 vaccines 

– Safety updates and review of myocarditis cases

– Discussion of benefit-risk balance for COVID-19 vaccines in adolescents and young 

adults

COVID-19 Work Group activities – May to June 2021

3
▪ Discussion around cases of myocarditis/pericarditis after mRNA COVID-19 

vaccination

Today’s ACIP meeting

4
▪ Discussion around cases of myocarditis/pericarditis after mRNA COVID-19 

vaccination

Today’s ACIP meeting

5

Vaccine Safety: 

Identifying and characterizing rare serious adverse events

Minimizing the occurrence of adverse events whenever possible

Communicating risks to the public, public health officials, and healthcare providers

Discussing known and potential benefits of vaccination with 

known and potential harms of vaccination 
▪ 148 myocarditis cases occurring around the time of vaccination

▪ Mostly reported among younger men aged 16–19, usually after second dose 

▪ Most cases were hospitalized, but 95% considered to be mild cases

▪ Israel determined a possible link between the second vaccine dose and the onset 

of myocarditis among young men aged 16 to 30

▪ Israel determined “risks for complications of coronavirus disease outweigh the 

risks posed by the vaccine’s side effects”

– “Myocarditis cases observed among teenagers aged 16–19 occurred in low rates and in 

most cases passed with no complications”

Myocarditis Cases Reported After mRNA vaccines in Israel

December 2020–May 2021

https://www.gov.il/en/departments/news/01062021-03 (updated June 2 2021) 6
▪ Since April 2021, there have been 

increased reports to Vaccine Adverse 

Event Reporting System (VAERS) of 

cases of inflammation of the heart 

happening after mRNA COVID-19 

vaccination 

Myocarditis and Pericarditis Following mRNA COVID-19 vaccination

7

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html
▪ Vaccine Safety Technical Work Group (VaST) reviewed data from Israel, 

Department of Defense and CDC/FDA safety surveillance systems

▪ COVID-19 vaccines Work Group reviewed data and discussed benefit/risk 

balance 

▪ Public ACIP meeting to review data and discuss benefit/risk assessment

Myocarditis and Pericarditis Following mRNA COVID-19 vaccination

ACIP Response 

8
▪ Discussion around cases of myocarditis/pericarditis after mRNA COVID-19 

vaccination

▪ Considerations around need for booster doses of COVID-19 vaccines

Today’s ACIP meeting

9
▪ Majority of Americans received at least 1 dose of COVID-19 vaccine

▪ Planning required if booster doses of COVID-19 vaccines needed

– Discussions around planning need to occur well in advance of future recommendations

– Planning discussions do not imply booster doses will be recommended 

▪ Discussions today around additional data needed to inform possible future 

recommendations

Booster Doses of COVID-19 vaccines

10
▪ Overview of myocarditis and pericarditis

Dr. Matthew Oster (CDC)

▪ Update on COVID-19 vaccine safety, including myocarditis after mRNA vaccines

Dr. Tom Shimabukuro (CDC)

▪ VaST assessment

Dr. Grace Lee (ACIP, VaST Chair)

▪ COVID-19 mRNA vaccines in adolescents and young adults: Benefit-risk discussion

Dr. Megan Wallace (CDC) and Dr. Sara Oliver (CDC)

▪ Discussion

▪ Public Comment

▪ Overview of data to inform recommendations for additional doses of COVID-19 vaccines 

Dr. Sara Oliver (CDC)

▪ Discussion

Today's Agenda

Wednesday, June 23
ACIP members

▪ Matthew Daley (chair)

▪ Beth Bell 

▪ Grace Lee

▪ Jose Romero

▪ Keipp Talbot

Ex-officio/government members

▪ FDA: Doran Fink, Rachel Zhang

▪ NIH: Chris Roberts

▪ IHS: Thomas Weiser, Uzo Chukwuma

▪ DOD: Bryan Schumacher

▪ CMS: Jeff Kelman

▪ BARDA: Christine Oshansky

▪ HHS: David Kim

CDC Lead

▪ Sara Oliver

Work group members

1

2

Liaisons

▪ AAFP: Jonathan Temte

▪ AAP: Sean O’Leary

▪ ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

▪ ACP: Jason Goldman

▪ AGS: Ken Schmader

▪ AIM: Rob Shechter (primary), 

Jane Zucker (alternate)

▪ AMA: Sandra Fryhofer

▪ ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

▪ APhA: Michael Hogue

▪ ASTHO: Marcus Plescia

▪ CSTE: Susan Lett (primary), 

Christine Hahn (alternate)

▪ IDSA: Jeff Duchin (primary), 

Carol Baker (alternate)

Liaisons, cont’d

▪ NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

▪ NACI: Matthew Tunis 

▪ NFID: Bill Schaffner (primary), 

Marla Dalton (alternate)

▪ NMA: Oliver Brooks

▪ SHEA: Marci Drees

Consultants

▪ Ed Belongia 

▪ Kathy Kinlaw 

▪ Dayna Matthew 

▪ Kathleen Neuzil 

▪ Stanley Perlman 

▪ Peter Szilagyi
▪ Doug Campos-Outcalt

▪ Mary Chamberland

▪ Thomas Clark

▪ Amanda Cohn

▪ Jillian Doss-Walker

▪ Kathleen Dooling

▪ Anthony Fiore

▪ Julia Gargano

▪ Sue Gerber

▪ Jack Gersten

▪ Susan Goldstein

▪ Monica Godfrey

▪ Sam Graitcer

▪ Lisa Grohskopf

▪ Stephen Hadler

CDC participants

13

▪ Rita Helfand

▪ Terri Hyde

▪ Cynthia Jorgensen

▪ Erin Kennedy

▪ Sarah Kidd

▪ Ram Koppaka

▪ Gayle Langley

▪ Megan Lindley

▪ Nicole Lindsey

▪ Ruth Link-Gelles

▪ Jessica MacNeil

▪ Lauri Markowitz

▪ Mona Marin

▪ Sarah Mbaeyi

▪ Meredith McMorrow

▪ Jennifer Verani

▪ Megan Wallace

▪ Cindy Weinbaum

▪ Melinda Wharton

▪ Kate Woodworth

▪ Yon Yu

▪ Danielle Moulia

▪ Rebecca Morgan

▪ Titilope Oduyebo

▪ Anita Patel

▪ Nicole Reisman

▪ Hannah Rosenblum

▪ Janell Routh

▪ Stephanie Schrag

▪ Heather Scobie

▪ Edwin Shanley

▪ Tom Shimabukuro

▪ Heidi Soeters

▪ Mark Sotir

▪ Stephanie Thomas

▪ Natalie Thornburg
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!